ACC
MCID: ADR016
MIFTS: 47

Adrenal Cortical Carcinoma (ACC)

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Adrenal Cortical Carcinoma

MalaCards integrated aliases for Adrenal Cortical Carcinoma:

Name: Adrenal Cortical Carcinoma 40 12
Adrenocortical Carcinoma 40 12 74 52 43 15
Carcinoma of the Adrenal Cortex 12
Adrenal Cortex Carcinoma 17
Acc 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3948
MeSH 43 D018268
NCIt 49 C9325
SNOMED-CT 67 2227007
ICD10 32 C74.0
UMLS 71 C0206686

Summaries for Adrenal Cortical Carcinoma

NIH Rare Diseases : 52 Adrenocortical carcinoma is a rare cancer affecting the outside of the adrenal glands (adrenal cortex ). These glands are on top of each kidney and are responsible for producing certain hormones and keeping blood pressure at normal levels. Adrenocortical carcinoma is relatively frequent in children compared to many other cancers, although the cancer may also affect adults. Girls are more often affected than boys. Symptoms of adrenocortical carcinoma may include pain in the abdomen, hypertension , weight gain, frequent urination and possibly deepening of the voice. These symptoms are due to the tumors causing excess secretion of hormones from the adrenal glands. Adrenocortical carcinoma may develop by chance alone, but at least 50% of the cancers are thought to be hereditary. There are a number of genes that have changes (mutations ) that can cause an adrenocortical carcinoma, including TP53 and IGF2 . There have been reports of both autosomal dominant inheritance and autosomal recessive inheritance. An adrenocortical carcinoma is diagnosed based on urine tests for abnormal levels of cortisol , the hormone released by the adrenal glands. Blood tests can also be conducted to measure levels of potassium and sodium in the blood. A CT scan or MRI may be used to search for a visible tumor in the adrenal cortex. Treatment options include surgical removal of the tumor, which is important to achieve a good long-term outlook. Chemotherapy , specifically a drug called mitotane , can be used to try to remove any remaining cancer after surgery.

MalaCards based summary : Adrenal Cortical Carcinoma, also known as adrenocortical carcinoma, is related to adenoid cystic carcinoma and adrenocortical carcinoma, hereditary. An important gene associated with Adrenal Cortical Carcinoma is HSD11B2 (Hydroxysteroid 11-Beta Dehydrogenase 2), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Steroid hormone biosynthesis. The drugs Dopamine and Bromocriptine have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal gland and adrenal cortex, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Wikipedia : 74 Adrenocortical carcinoma (ACC) is an aggressive cancer originating in the cortex (steroid... more...

Related Diseases for Adrenal Cortical Carcinoma

Diseases related to Adrenal Cortical Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 700)
# Related Disease Score Top Affiliating Genes
1 adenoid cystic carcinoma 33.3 VIM TP53 MUC1 ACTC1 ACCS
2 adrenocortical carcinoma, hereditary 31.6 TP53 NR5A1 MIR483 IGF2
3 hypokalemia 31.1 POMC HSD11B2 CYP11B1
4 spindle cell sarcoma 30.9 VIM MUC1 ACTC1
5 li-fraumeni syndrome 30.8 ZNRF3 TP53 MIR483 IGF2 ACCS
6 acinar cell carcinoma 30.8 TP53 SYP CHGA ACCS
7 reticulum cell sarcoma 30.8 VIM MUC1 ACTC1
8 malignant pheochromocytoma 30.8 SYP MIR483 CHGA
9 adenoma 30.7 TP53 POMC MUC1 HSD11B2 CYP11B2 CYP11B1
10 conn's syndrome 30.7 POMC HSD11B2 CYP11B2 CYP11B1 CHGA
11 multiple endocrine neoplasia, type i 30.6 SYP POMC MIR483 CHGA
12 angiomyolipoma 30.6 VIM MLANA ACTC1
13 sarcoma 30.6 VIM TP53 MUC1 IGF1R ACTC1
14 beckwith-wiedemann syndrome 30.5 TP53 MIR675 MIR483 IGF2 IGF1R ACCS
15 renal cell carcinoma, nonpapillary 30.5 VIM TP53 MUC1 MIR139 IGF1R ACTC1
16 angiosarcoma 30.5 VIM TP53 MUC1 MLANA
17 pleomorphic adenoma 30.5 VIM TP53 MUC1 ACTC1
18 hypoadrenocorticism, familial 30.5 POMC NR5A1 CYP11B2
19 mucoepidermoid carcinoma 30.5 TP53 MUC1 CHGA ACTC1
20 tubular adenocarcinoma 30.5 SYP MUC1 CHGA
21 horseshoe kidney 30.5 SYP CHGA ACTC1
22 carcinosarcoma 30.4 VIM TP53 MUC1 ACTC1
23 adrenal hypoplasia, congenital 30.4 POMC NR5A1 EPPIN
24 gangliocytoma 30.4 SYP POMC CHGA
25 primary pigmented nodular adrenocortical disease 30.4 SYP POMC MIR483 CHGA
26 thyroid gland medullary carcinoma 30.4 SYP POMC CHGA
27 pseudohermaphroditism 30.4 POMC NR5A1 EPPIN
28 small cell carcinoma 30.3 TP53 SYP MUC1 CHGA
29 carney complex variant 30.3 POMC MLANA CYP11B1 ACCS
30 lipoid congenital adrenal hyperplasia 30.3 POMC NR5A1 CYP11B2 CYP11B1
31 neuroendocrine tumor 30.3 SYP POMC IGF1R CHGA
32 papilloma of choroid plexus 30.3 TP53 SYP MUC1 IGF2
33 pituitary adenoma, prolactin-secreting 30.3 POMC NR5A1 CHGA
34 oncocytoma 30.3 VIM SYP MUC1
35 endocrine gland cancer 30.2 SYP MIR675 MIR483 MIR139 CHGA
36 hemangioma 30.2 TP53 SYP MUC1 IGF2 CHGA ACTC1
37 gastrointestinal stromal tumor 30.2 VIM TP53 SYP IGF2 CHGA ACTC1
38 teratoma 30.2 VIM TP53 SYP CHGA ACTC1
39 retroperitoneal sarcoma 30.2 MLANA ACCS
40 neurofibroma 30.1 VIM TP53 SYP MUC1 MLANA ACTC1
41 adrenal adenoma 30.1 POMC MIR483 IGF2 HSD11B2 EPPIN CYP11B2
42 adrenal rest tumor 30.0 POMC NR5A1 EPPIN CYP11B2 CYP11B1
43 rhabdomyosarcoma 30.0 VIM TP53 SYP IGF2 IGF1R ACTC1
44 adrenal cortical adenoma 29.9 SYP POMC NR5A1 MLANA MIR483 IGF2
45 wilms tumor 1 29.7 TP53 SYP NR5A1 MIR483 IGF2 IGF1R
46 adrenal carcinoma 29.3 ZNRF3 TP53 SYP POMC NR5A1 MLANA
47 adrenocortical carcinoma with pure aldosterone hypersecretion 12.5
48 aplasia cutis congenita, nonsyndromic 12.0
49 corpus callosum, agenesis of 12.0
50 agenesis of the corpus callosum with peripheral neuropathy 11.6

Graphical network of the top 20 diseases related to Adrenal Cortical Carcinoma:



Diseases related to Adrenal Cortical Carcinoma

Symptoms & Phenotypes for Adrenal Cortical Carcinoma

GenomeRNAi Phenotypes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CHGA CYP11B1 HSD11B2 IGF1R IGF2 POMC

MGI Mouse Phenotypes related to Adrenal Cortical Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.9 ACTC1 CHGA CYP11B1 CYP11B2 HSD11B2 IGF1R
2 endocrine/exocrine gland MP:0005379 9.61 CHGA CYP11B1 CYP11B2 IGF1R IGF2 NR5A1
3 muscle MP:0005369 9.23 ACTC1 CHGA CYP11B1 HSD11B2 IGF1R IGF2

Drugs & Therapeutics for Adrenal Cortical Carcinoma

Drugs for Adrenal Cortical Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
3 Dopamine Agents Phase 4
4 Antiparkinson Agents Phase 4
5 Dopamine agonists Phase 4
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7
Mecasermin Approved, Investigational Phase 3 68562-41-4
8
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Etoposide Approved Phase 3 33419-42-0 36462
12
Mitotane Approved Phase 3 53-19-0 4211
13
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
14 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
15 Anti-Bacterial Agents Phase 3
16 Antibiotics, Antitubercular Phase 3
17
Liposomal doxorubicin Phase 3 31703
18 Immunologic Factors Phase 3
19 Anesthetics Phase 3
20 Anesthetics, General Phase 3
21 Central Nervous System Depressants Phase 3
22 Anesthetics, Intravenous Phase 3
23 Adjuvants, Immunologic Phase 3
24 Liver Extracts Phase 3
25 Cola Phase 3
26 Narcotics Phase 3
27 Analgesics, Opioid Phase 3
28 Adjuvants, Anesthesia Phase 3
29 Analgesics Phase 3
30 Etoposide phosphate Phase 3
31 Topoisomerase Inhibitors Phase 3
32 Antineoplastic Agents, Hormonal Phase 3
33 Podophyllotoxin Phase 3 518-28-5
34
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
35
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
36
Indinavir Approved Phase 2 150378-17-9 5362440
37
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
38
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
39
Etomidate Approved Phase 1, Phase 2 33125-97-2 36339 667484
40
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
41
acetic acid Approved Phase 2 64-19-7 176
42
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
43
Tamoxifen Approved Phase 2 10540-29-1 2733526
44
Sodium citrate Approved, Investigational Phase 2 68-04-2
45
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
46
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
47
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
48
Ipilimumab Approved Phase 2 477202-00-9
49
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
50
Pembrolizumab Approved Phase 2 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
2 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
3 First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
4 Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
5 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
7 Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence Recruiting NCT00777244 Phase 3 MITOTANE
8 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
9 Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
10 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
12 Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
13 Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
14 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
15 A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors Completed NCT01262235 Phase 1, Phase 2 TKM-080301
16 A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
17 A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC) Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
18 Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy Completed NCT00453895 Phase 2 Sunitinib
19 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
20 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
21 An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201) Completed NCT00264433 Phase 2 ADH -1 (Exherin™)
22 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
23 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
24 Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
25 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
26 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
27 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
28 Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
29 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
30 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
31 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
32 A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
33 An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
34 Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
35 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
36 MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Patients Previously Treated With Fluoropyrimidine and Platinum Agents MiCADO Study Recruiting NCT02007148 Phase 2 capecitabine;Docetaxel
37 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
38 A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
39 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
40 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04187404 Phase 1, Phase 2
41 Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
42 Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma Terminated NCT02720484 Phase 2 Nivolumab
43 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
44 Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone Terminated NCT00778817 Phase 2 mitotane
45 A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex. Withdrawn NCT00469469 Phase 2 Bevacizumab
46 Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
47 A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
48 A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
49 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
50 A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed NCT01981525 Phase 1 Metformin

Search NIH Clinical Center for Adrenal Cortical Carcinoma

Cochrane evidence based reviews: adrenocortical carcinoma

Genetic Tests for Adrenal Cortical Carcinoma

Anatomical Context for Adrenal Cortical Carcinoma

MalaCards organs/tissues related to Adrenal Cortical Carcinoma:

40
Cortex, Adrenal Gland, Adrenal Cortex, Liver, Kidney, Lung, Thyroid

Publications for Adrenal Cortical Carcinoma

Articles related to Adrenal Cortical Carcinoma:

(show top 50) (show all 2854)
# Title Authors PMID Year
1
Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. 61
31241762 2020
2
Correction to: Adrenocortical carcinoma complicated by renal thrombotic microangiopathy, a case-series. 61
32039708 2020
3
The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. 61
31586196 2020
4
Macroscopic Fat in Adrenocortical Carcinoma: A Systematic Review. 61
31691613 2020
5
Prognostic significance of immunohistochemical markers in adrenocortical carcinoma. 61
30499377 2020
6
Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods. 61
31856409 2020
7
Adrenalectomy for non-neuroblastic pathology in children. 61
31691026 2020
8
Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database. 61
31272813 2020
9
Comparative Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging Manual for Adrenocortical Carcinoma. 61
31493191 2020
10
Regulation of stimulus-induced interleukin-8 gene transcription in human adrenocortical carcinoma cells - Role of AP-1 and NF-κB. 61
31634687 2020
11
Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. 61
32033200 2020
12
Generation and characterization of a mitotane-resistant adrenocortical cell line. 61
31910152 2020
13
Endoplasmic Reticulum Chaperone Calmegin Is Upregulated in Aldosterone-Producing Adenoma and Associates With Aldosterone Production. 61
31865789 2020
14
Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos. 61
31945643 2020
15
Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis. 61
31884045 2020
16
Current role of open surgery in adrenal tumors. 61
32038016 2020
17
PD-1 Blockade in Advanced Adrenocortical Carcinoma. 61
31644329 2020
18
Adrenocortical carcinoma in atypical Beckwith-Wiedemann syndrome due to loss of methylation at imprinting control region 2. 61
31612591 2020
19
Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. 61
31900481 2020
20
Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma. 61
31917677 2020
21
Adrenocortical carcinoma complicated by renal thrombotic microangiopathy, a case-series. 61
32000700 2020
22
Images - Oncocytic adrenocortical carcinoma: A rare tumor variant. 61
31658010 2020
23
Comparison between functional and non-functional adrenocortical carcinoma. 61
31543320 2020
24
Adrenocortical Carcinoma with Inferior Vena Cava Thrombus on 18F-FDG-PET-Computed Tomography. 61
31949384 2020
25
Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma. 61
31963898 2020
26
The diagnosis and treatment of adrenocortical carcinoma in pregnancy: a case report. 61
31964355 2020
27
Adrenocortical carcinoma in a young adult male with chronic urticaria: A case report and literature review. 61
31918158 2020
28
The outcome of childhood adrenocortical carcinoma in Egypt: A model from developing countries. 61
31971470 2020
29
Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience. 61
31777255 2020
30
Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma. 61
31998416 2020
31
A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression. 61
31561992 2020
32
Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy. 61
30910391 2020
33
Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy. 61
31522749 2020
34
Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management. 61
31894378 2020
35
Disease-free interval and tumor functional status can be used to select patients for resection/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study. 61
31447392 2020
36
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. 61
31984451 2020
37
Metabolic Profiling Reveals a Dependency of Human Metastatic Breast Cancer on Mitochondrial Serine and One-Carbon Unit Metabolism. 61
31941752 2020
38
Clinical Characteristics and Follow-Up Results of Adrenal Incidentaloma. 61
31958848 2020
39
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. 61
31812554 2020
40
Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment. 61
31513709 2020
41
A Micellar Mitotane Formulation with High Drug-Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models. 61
31596553 2020
42
HOXC11 functions as a novel oncogene in human colon adenocarcinoma and kidney renal clear cell carcinoma. 61
31923422 2020
43
Effects of Adipocyte-derived Factors on the Adrenal Cortex. 61
31613736 2020
44
National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress? 61
31361313 2019
45
Tauroursodeoxycholic acid mediates endoplasmic reticulum stress and autophagy in adrenocortical carcinoma cells. 61
31814847 2019
46
Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial. 61
31276163 2019
47
Reduced expression of ferroportin1 and ceruloplasmin predicts poor prognosis in adrenocortical carcinoma. 61
31442954 2019
48
Preoperative systemic inflammatory markers are prognostic indicators in recurrent adrenocortical carcinoma. 61
31733070 2019
49
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆. 61
31536779 2019
50
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. 61
31639772 2019

Variations for Adrenal Cortical Carcinoma

Cosmic variations for Adrenal Cortical Carcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM89368095 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.133T>C p.S45P 3:41224645-41224645 8

Expression for Adrenal Cortical Carcinoma

Search GEO for disease gene expression data for Adrenal Cortical Carcinoma.

Pathways for Adrenal Cortical Carcinoma

GO Terms for Adrenal Cortical Carcinoma

Biological processes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of blood pressure GO:0008217 9.58 POMC CYP11B1 CHGA
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.48 TP53 MUC1
3 C21-steroid hormone biosynthetic process GO:0006700 9.46 CYP11B2 CYP11B1
4 cellular response to potassium ion GO:0035865 9.43 CYP11B2 CYP11B1
5 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.37 TP53 MUC1
6 cortisol biosynthetic process GO:0034651 9.32 CYP11B2 CYP11B1
7 cortisol metabolic process GO:0034650 9.26 CYP11B2 CYP11B1
8 aldosterone biosynthetic process GO:0032342 9.16 CYP11B2 CYP11B1
9 regulation of blood volume by renal aldosterone GO:0002017 8.96 HSD11B2 CYP11B2
10 glucocorticoid biosynthetic process GO:0006704 8.8 HSD11B2 CYP11B2 CYP11B1

Molecular functions related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 corticosterone 18-monooxygenase activity GO:0047783 8.96 CYP11B2 CYP11B1
2 steroid 11-beta-monooxygenase activity GO:0004507 8.62 CYP11B2 CYP11B1

Sources for Adrenal Cortical Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....